Nextcure (NXTC) closed at $5.98 on November 10, 2026, down 4.6% from the previous close, on volume of 80,295 shares (30-day average 62,111).
Data as of November 10, 2026.
NextCure GAAP EPS of -$1.29 misses by $0.39
Seeking Alpha News (Tue, 10-Nov 5:00 PM ET)
NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results
Globe Newswire (Tue, 10-Nov 4:05 PM ET)
Market Chameleon (Tue, 14-Jul 5:52 AM ET)
NextCure and Avere Merger Signals Ambitious Push Toward Once-Weekly Oral IL-23 Therapy
Market Chameleon (Tue, 14-Jul 3:05 AM ET)
NextCure Raises $21.5 Million in Private Placement, Extends Cash Runway Into 2027
Market Chameleon (Wed, 12-Nov 3:49 AM ET)
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Nextcure trades on the NASDAQ stock market under the symbol NXTC.
As of November 11, 2026, NXTC stock price climbed to $6.27 with 88,093 million shares trading.
NXTC has a beta of 3.49, meaning it tends to be more sensitive to market movements. NXTC has a correlation of 0.06 to the broad based SPY ETF.
NXTC has a market cap of $28.70 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, NXTC traded as high as $30.84 and as low as $1.55.
The top ETF exchange traded funds that NXTC belongs to (by Net Assets): VTI, VXF, IWC, DFMC, DFAC.
NXTC has underperformed the market in the last year with a return of -26.2%, while the SPY ETF gained +12.6%. In the last 3 month period, NXTC fell short of the market, returning -8.3%, while SPY returned -1.5%. However, in the most recent 2 weeks NXTC has outperformed the stock market by returning +9.7%, while SPY returned -1.3%.
NXTC support price is $5.40 and resistance is $6.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NXTC shares will trade within this expected range on the day.
